Full Data For Seattle Genetics’ Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates

Seattle Genetics and partner Takeda are revising their regulatory strategy and will file their antibody drug conjugate SGN-35 in the first quarter of 2011 for both Hodgkin's lymphoma and anaplastic large cell lymphoma, following a positive reception for their pivotal data at the American Society of Hematology annual meeting.